Patent · US Active

β-lactamase inhibitor compounds

US9623014B2 · kind B2 · utility

2Cited by

3References

22Claims

0Family size

Assignee

Entasis Therapeutics, Inc. · US

Inventors

Helen Mcguire · Watertown, US
Shanta Bist · Nashua, US
Neil Bifulco, Jr. · Waltham, US
Liang Zhao · Lexington, US
Ye Wu · Waltham, US
Hoan Huynh · Waltham, US
Hui Xiong · Waltham, US
Janelle Comita-Prevoir · Northborough, US
Daemian Dussault · Waltham, US
Bolin Geng · Andover, US
Brendan Chen · Sudbury, US
Thomas Francois Durand-Reville · Belmont, US
Satenig Guler · Waltham, US

Key dates

Filing date	Feb 29, 2016
Grant date	Apr 18, 2017
Priority date	—
Expiry date	Feb 29, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia):or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.